Den Europæiske Union - dansk - EMA (European Medicines Agency)

novartis europharm limited  - capmatinib dihydrochloride monohydrate - carcinom, ikke-småcellet lunge - antineoplastiske midler - tabrecta as monotherapy is indicated for the treatment of adult patients with advanced non small cell lung cancer (nsclc) harbouring alterations leading to mesenchymal epithelial transition factor gene exon 14 (metex14) skipping, who require systemic therapy following prior treatment with immunotherapy and/or platinum based chemotherapy.

Den Europæiske Union - dansk - EMA (European Medicines Agency)

les laboratoires servier - ivosidenib - leukemia, myeloid, acute; cholangiocarcinoma - antineoplastiske midler - tibsovo in combination with azacitidine is indicated for the treatment of adult patients with newly diagnosed acute myeloid leukaemia (aml) with an isocitrate dehydrogenase-1 (idh1) r132 mutation who are not eligible to receive standard induction chemotherapy (see section 5. tibsovo monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic cholangiocarcinoma with an idh1 r132 mutation who were previously treated by at least one prior line of systemic therapy.

Den Europæiske Union - dansk - EMA (European Medicines Agency)

novartis europharm limited  - lutetium (177lu) vipivotide tetraxetan - prostatic neoplasmer, kastration-resistent - terapeutiske radioaktive lægemidler - pluvicto in combination with androgen deprivation therapy (adt) with or without androgen receptor (ar) pathway inhibition is indicated for the treatment of adult patients with progressive prostate-specific membrane antigen (psma)-positive metastatic castration-resistant prostate cancer (mcrpc) who have been treated with ar pathway inhibition and taxane based chemotherapy.

Den Europæiske Union - dansk - EMA (European Medicines Agency)

novartis europharm limited  - gozetotide - radionuklidbilleddannelse - diagnostiske radioaktive lægemidler - dette lægemiddel er kun til diagnostisk brug. locametz, after radiolabelling with gallium 68, is indicated for the detection of prostate specific membrane antigen (psma) positive lesions with positron emission tomography (pet) in adults with prostate cancer (pca) in the following clinical settings:primary staging of patients with high risk pca prior to primary curative therapy,suspected pca recurrence in patients with increasing levels of serum prostate specific antigen (psa) after primary curative therapy,identification of patients with psma positive progressive metastatic castration resistant prostate cancer (mcrpc) for whom psma targeted therapy is indicated (see section 4.

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

stada arzneimittel ag - memantinhydrochlorid - filmovertrukne tabletter - 10 mg

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

stada arzneimittel ag - memantinhydrochlorid - filmovertrukne tabletter - 20 mg

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

amneal pharma europe limited - memantinhydrochlorid - filmovertrukne tabletter - 5/10/15/20 mg

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

doc generici s.r.l. - memantinhydrochlorid - filmovertrukne tabletter - 10 mg

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

doc generici s.r.l. - memantinhydrochlorid - filmovertrukne tabletter - 20 mg

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

krka d.d. novo mesto - memantinhydrochlorid - filmovertrukne tabletter - 10 mg